Classical Hodgkin's lymphoma arising in different host's conditions: Pathobiology parameters, therapeutic options, and outcome

American Journal of Hematology

Volumn 86, Issue 2, 2011, Pages 170-179

  Carbone, Antonino ^a   Spina, Michele ^a   Gloghini, Annunziata ^b   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BLEOMYCIN; CARMUSTINE; CD15 ANTIGEN; CD30 ANTIGEN; CD79A ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; INTERFERON REGULATORY FACTOR 4; LACTATE DEHYDROGENASE; LATENT MEMBRANE PROTEIN 1; NAVELBINE; OCTAMER TRANSCRIPTION FACTOR 2; PREDNISONE; PROCARBAZINE; PROTEIN BCL 2; PROTEIN KINASE B; RITUXIMAB; STAT PROTEIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR PAX5; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE SULFATE;

ABDOMEN; ADULT DISEASE; ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW; BONE MARROW RESCUE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CHILDHOOD CANCER; CLASSICAL HODGKIN LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA TYPE POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; CLINICAL PROTOCOL; COMORBIDITY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG FATALITY; DRUG TREATMENT FAILURE; EOSINOPHIL; EPSTEIN BARR VIRUS INFECTION; FIBROBLAST; GERIATRIC CARE; GOLD STANDARD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTIOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED CLASSICAL HODGKIN LYMPHOMA; IATROGENIC DISEASE; IMMUNE DEFICIENCY; IMMUNE STATUS; IMMUNOCOMPROMISED PATIENT; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KIDNEY TRANSPLANTATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE; MAST CELL; MEDIASTINUM; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PHENOTYPE; PLASMA CELL; POSTOPERATIVE COMPLICATION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RADIATION DOSE; REED STERNBERG CELL; RETICULUM CELL; REVIEW; SEX DIFFERENCE; SPLEEN; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; AGED; CHILD; HODGKIN DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOPROLIFERATIVE DISORDERS; TISSUE TRANSPLANTATION; TREATMENT OUTCOME;

EID: 78851472242     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21910     Document Type: Review

References (167)

1. Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
2. Stein H, Delsol G, Pileri SA, et al. Classical Hodgkin lymphoma, introduction. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. pp 326-329.
3. Raphael M, Said J, Borish B, et al. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, et al., editors.World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. pp 340-342.
4. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors.World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008, pp 343-349.
5. Jaffe ES, Stein H, Swerdlow SH, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. pp 267-268.
6. Gaulard P, Swerdlow SH, Harris SH, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors.World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008, pp 350-351.
7. Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 1999; 93: 2319-2326.
8. Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: Classification and treatment. Oncologist 2008; 13: 577-585.
9. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol 2007; 60: 1365-1372.
10. Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS 2009; 4: 3-10.
11. Said JW. Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol 2007; 14: 189-194.
12. Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780-789.
13. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-2092.
14. Carbone A, Gloghini A, Aldinucci D, et al. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol 2002; 117: 366-372.
15. Gloghini A, Carbone A. Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? Int J Cancer 2007; 120: 2753-2754.
16. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 4283-4297.
17. Aldinucci D, Lorenzon D, Cattaruzza L, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumour cell growth and microenvironmental interactions. Int J Cancer 2008; 122: 769-776.
18. Fischer M, Juremalm M, Olsson N, et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003; 107: 197-201.
19. Niens M, Visser L, Nolte IM, et al. Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22. Br J Haematol 2008; 140: 527-536.
20. Van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999; 154: 1685-1691.
21. Hanamoto H, Nakayama T, Miyazato H, et al. Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol 2004; 164: 997-1006.
22. Baumforth KR, Birgersdotter A, Reynolds GM, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008; 173: 195-204.
23. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin's lymphoma: Clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol 2005; 23: 5739-5745.
24. Marshall NA, Culligan DJ, Tighe J, et al. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol 2007; 35: 596-604.
25. Maggio E, van den Berg A, Diepstra A, et al. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002; 13: 52-56.
26. Uchihara JN, Krensky AM, Matsuda T, et al. Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1. Int J Cancer 2005; 114: 747-755.
27. Spitz MR, Sider JG, Johnson CC. Ethnic patterns of Hodgkin's disease incidence among children and adolescents in the United States, 1973-82. J Natl Cancer Inst 1986; 76: 235-239.
28. Cleary SF, Link MP, Donaldson SS. Hodgkin's disease in the very young. Int J Radiat Oncol Biol Phys 1994; 28: 77-83.
29. Jarrett RF. Viruses and Hodgkin's lymphoma. Ann Oncol 2002; 13( Suppl 1): 23-29.
30. Alexander FE, Jarrett RF, Lawrence D. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: Prior infection by EBV and other agents. Br J Cancer 2000; 82: 1117-1121.
31. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349: 1324-1332.
32. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328-1337.
33. Donaldson SS. Pediatric Hodgkin's disease-Up, up, and beyond. Int J Radiat Oncol Biol Phys 2002; 54: 1-8.
34. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 2003; 21: 2026-2033.
35. Ruhl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: An interim report at 5 years of the German GPOH-HD 95 Trial. Int J Radiat Oncol Biol Phys 2001; 51: 1209-1218.
36. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy: Results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000; 18: 1500-1507.
37. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 2004; 22: 62-68.
38. Arya L, Dinand V, Thavaraj V, et al. Hodgkin's disease in Indian children: Outcome with chemotherapy alone. Pediatr Blood Cancer 2006; 46: 26-34.
39. Hakvoort-Cammel FG, Buitendijk S, van den Heuvel-Eibrink M, Hählen K. Treatment of pediatric Hodgkin disease avoiding radiotherapy: Excellent outcome with the Rotterdam-HD-84-Protocol. Pediatr Blood Cancer 2004; 43: 8-16.
40. Nachman J, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20: 3765-3771.
41. Donaldson SS, Link MP, Weinstein RJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low risk Hodgkin's disease. J Clin Oncol 2007; 25: 332-337.
42. Schellong G, Potter R, Brämswig J, et al. High cure rates and reduced long term toxicity in pediatric Hodgkin's disease: The German-Austrian Multicenter Trial DAL-HD-90.The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999; 17: 3736-3744.
43. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood 2009; 114: 2051-2059.
44. Clinical Trials.gov [a service of the US National Institutes of Health]. Chemotherapy with or without additional chemotherapy and/or radiation therapy in treating children with newly diagnosed Hodgkin's disease (NCT00025259) [online]. Available at: Accessed August 16, 2010.
45. Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 2004; 22: 4541-4550.
46. Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: Preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol 2002; 13( Suppl 1): 107-111.
47. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-796.
48. Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008; 111: 2977-2983.
49. Bosetti C, Levi F, Ferlay J, et al. The recent decline in mortality from Hodgkin lymphomas in central and eastern Europe. Ann Oncol 2009; 20: 767-774.
50. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Longterm cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-3439.
51. Brusamolino E, Baio A, Orlandi E, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up. Clin Cancer Res 2006; 12: 6487-6493.
52. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 3128-3135.
53. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916-1927.
54. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3601-3608.
55. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 2004; 22: 2835-2841.
56. Engert A, Pluetschow A, Eich HT, et al. Combined modality treatment of two or four cycles of ABVD followed by IFRT in the treatment of patients with early stage Hodgkin's lymphoma: Update interim analysis of the randomised HD10 study of the German Hodgkin study group (GHSG). Blood 2005; 106: 750a.
57. Diehl V, Brillant C, Engert A, et al. Recent interim analysis of the HD11 trial of the GHSG: Intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin's lymphoma. Blood 2005; 106: 240a-241a.
58. Ferme C, Divine M, Vranovsky A, et al. Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-U trial. Blood 2005; 106: 240a.
59. Rueda Dominguez A, Marquez A, Gumá J, et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: Results after 7 years of a prospective study. Ann Oncol 2004; 15: 1798-1804.
60. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 3483-3489.
61. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634-4642.
62. Eghbali H, Brice P, Creemers GY, et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-F trial. Blood 2005: 106: 240a.
63. DeVita VTJr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587-595.
64. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295-1306.
65. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37.
66. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986; 104: 739-746.
67. Somers R, Carde P, Henry-Amar M, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12: 279-287.
68. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 1996; 14: 1421-1430.
69. Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy-Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997; 15: 1638-1645.
70. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-1484.
71. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 2003; 21: 607-614.
72. Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23: 9208-9218.
73. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396-2406.
74. Fermé C, Mounier N, Casasnovas O, et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 107: 4636-4642.
75. Eich HT, Gossmann A, Engert A, et al. A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma-Analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2007; 69: 1187-1192.
76. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27: 805-811.
77. Gianni AM, Rambaldi A, Pulsoni A, et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma: A randomized trial of the Michelangelo, GITIL and IIL cooperative groups. J Clin Oncol 2008; 26:Abs. 8506.
78. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
79. Federico M, Bellei M, Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003; 21: 2320-2325.
80. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 Study. J Clin Oncol 2009; 27: 4548-4554.
81. Carella AM, Bellei M, Brice P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: Long-term results. Haematologica 2009; 94: 146-148.
82. Carbone A, Gloghini A, Aiello A, et al. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol 2010; 41: 621-631.
83. Zinzani PL, Martelli M, Magagnoli M, et al. Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood 1998; 92: 790-794.
84. Calvo KR, Traverse-Glehen A, Pittaluga S, Jaffe ES. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: Implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. Adv Anat Pathol 2004; 11: 227-238.
85. García JF, Mollejo M, Fraga M, et al. Large B-cell lymphoma with Hodgkin's features. Histopathology 2005; 47: 101-110.
86. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23: 5052-5060.
87. Jarrett RF, Stark GL, White J, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: A population-based study. Blood 2005; 106: 2444-2451.
88. Diepstra A, van Imhoff GW, Schaapveld M, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 2009; 27: 3815-3821.
89. Levis A, Depaoli L, Urgesi A, et al. Probability of cure in elderly Hodgkin's disease patients. Haematologica 1994; 79: 46-54.
90. Weekes CD, Vose JM, Lynch JC, et al. Hodgkin's disease in the elderly: Improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 2002; 20: 1087-1093.
91. Macpherson N, Klasa RJ, Gascoyne R, et al. Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): A phase II study. Leuk Lymphoma 2002; 43: 1395-1402.
92. Kim HK, Silver B, Li S, et al. Hodgkin's disease in elderly patients (≥60): Clinical outcome and treatment strategies. Int J Radiat Oncol Biol Phys 2003; 56: 556-560.
93. van Spronsen DJ, Janssen-Heijnen ML, Breed WP, Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 1999; 78: 315-319.
94. Diaz-Pavon JR, Cabanillas F, Majlis A, Hagemeister FB. Outcome of Hodgkin's disease elderly patients. Hematol Oncol 1995; 13: 19-24.
95. Levis A, Depaoli L, Bertini M, et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica 1996; 81: 450-456.
96. Specht L, Nissen NI. Hodgkin's disease and age. Eur J Haematol 1989; 43: 127-135.
97. Erdkamp FL, Breed WP, Bosch LJ, et al. Hodgkin disease in the elderly. A registry-based analysis. Cancer 1992; 70: 830-834.
98. Stark GL, Wood KM, Jack F, et al. Hodgkin's disease in the elderly: A population-based study. Br J Haematol 2002; 119: 432-440.
99. Enblad G, Glimelius B, Sundström C. Treatment outcome in Hodgkin's disease in patients above the age of 60: A population-based study. Ann Oncol 1991; 2: 297-302.
100. Taylor PR, Angus B, Owen JP, Proctor SJ. Hodgkin's disease: A population-adjusted clinical epidemiology study (PACE) of management at presentation. Northern Region Lymphoma Group. QJM 1998; 91: 131-139.
101. Klimm B, Diehl V, Engert A. Hodgkin's lymphoma in the elderly: A different disease in patients over 60. Oncology (Williston Park) 2007; 21: 982-990.
102. Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 2004; 15: 123-128.
103. Landgren O, Algernon C, Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003; 88: 438-444.
104. Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol 2005; 16: 124-131.
105. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55: 241-252.
106. Nakamura S, Jaffe ES, Swerdlow SH. EBV positive diffuse large B-cell lymphoma of the elderly in lymphoproliferative diseases associated with primary immune disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors.World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. pp 243-244.
107. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: A study of 96 patients. Clin Cancer Res 2007; 13: 5124-5132.
108. Shimoyama Y, Asano N, Kojima M, et al. Age-related EBV-associated B-cell lymphoproliferative disorders: Diagnostic approach to a newly recognized clinicopathological entity. Pathol Int 2009; 59: 835-843.
109. Asano N, Yamamoto K, Tamaru J, et al. Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: Comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 2009; 113: 2629-2636.
110. Murase T, Fujita A, Ueno H, et al. A case of age-related EBV-associated B-cell lymphoproliferative disorder metachronously showing two distinct morphologic appearances, one of a polymorphic disease resembling classical Hodgkin lymphoma, and the other of a large-cell lymphoma. Int J Hematol 2009; 89: 80-85.
111. Serraino D, Boschini A, Carrieri P, et al. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS 2000; 14: 553-559.
112. Franceschi S, Dal Maso L, Pezzotti P, et al.Cancer and AIDS Registry Linkage Study. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr 2003; 34: 84-90.
113. Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV cohort study. J Clin Oncol 2009; 113: 5737-5742.
114. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108: 3786-3791.
115. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-890.
116. Levine AM. Hodgkin lymphoma: To the HAART of the matter. Blood 2006; 108: 3630.
117. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 1995; 13: 1758-1767.
118. Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related NHL in the era of HAART. Clin Infect Dis 2009; 37: 1556-1564.
119. Chimienti E, Spina M, Gastaldi R, et al. Clinical characteristics and outcome of 290 patients (pts) with Hodgkin's disease and HIV infection (HD-HIV) in pre and HAART (highly active antiretroviral therapy) era. Ann Oncol 2008; 19: iv136; abs 168.
120. Errante D, Tirelli U, Gastaldi R, et al. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. Cancer 1994; 73: 437-444.
121. Errante D, Gabarre J, Ridolfo AL, et al. Hodgkin's disease in 35 patients with HIV infection: An experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol 1999; 10: 189-195.
122. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine and dacarbazine with granulocyte-colony-stimulating factor CSF in HIV infected patients with newly diagnosed Hodgkin's disease: A prospective, multi-institutional AIDS Clinical Trials Group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24: 444-450.
123. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
124. Spina M, Gabarre J, Rossi G, et al. Stanford V and concomitant HAART in 59 patients with Hodgkin's disease and HIV infection. Blood 2002; 100: 1984-1988.
125. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 2003; 14: 1562-1569.
126. Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007; 92: 191-198.
127. Spina M, Rossi G, Antinori A, et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV). Ann Oncol 2008; 19: iv152; abs227.
128. Krishnan A, Molina A, Zaia J, et al. Durable remission with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005; 105: 874-878.
129. Serrano D, Carrion R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol 2005; 33: 487-494.
130. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: Long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114: 1306-1313.
131. Hayashi RJ, Kraus MD, Patel AL, et al. Post-transplant lymphoproliferative disease in children: Correlation of histology to clinical behaviour. J Pediatr Hematol Oncol 2001; 23: 14-18.
132. Midthum D, McDougall J, Peters S, Scott JP. Medical management and complications in the lung transplant recipient. Mayo Clin Proc 1997; 72: 175-184.
133. Rohr JC, Wagner HJ, Lauten M, et al. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant 2008; 12: 426-431.
134. Knight JS, Tsodikov A, Cibrik DM, et al. Lymphoma after solid organ transplantation: Risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009; 27: 3354-3362.
135. Adams H, Campidelli C, Dirnhofer S, et al. Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. Expert Opin Ther Targets 2009; 13: 1137-1145.
136. Bierman PJ, Vose JM, Langnas AN, et al. Hodgkin's disease following solid organ transplantation. Ann Oncol 1996; 7: 265-270.
137. Dharnidharka VR, Douglas VK, Hunger SP, Fennell RS. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient. Pediatr Transplant 2004; 8: 87-90.
138. Krishnamurthy S, Hassan A, Frater JL, et al. Pathologic and clinical features of Hodgkin lymphoma-like posttransplant lymphoproliferative disease. Int J Surg Pathol 2010; 18: 278-285.
139. Garnier JL, Lebranchu Y, Dantal J, et al. Hodgkin's disease after transplantation. Transplantation 1996; 61: 71-76.
140. Goyal RK, McEvoy L, Wilson DB. Hodgkin's disease after renal transplantation: I. Childhood. J Pediatr Hematol Oncol 1996; 18: 392-395.
141. Pitman SD, Huang Q, Zuppan CW, et al. Hodgkin's lymphoma-like posttransplantation lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol 2006; 30: 470-476.
142. Pham PT, Wilkinson AH, Gritsch HA, et al. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with post-transplant lymphoproliferative disease. Transplant Proc 2002; 34: 1178-1181.
143. Hasserjian RP, Chen S, Perkins SL, et al. Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol 2009; 22: 1532-1540.
144. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328: 1317-1321.
145. Diehl V, Stein H, Hummel M, et al. Hodgkin's lymphoma: Biology and treatment strategies for primary refractory and relapsed disease. Hematology Am Soc Hematol Program 2003; 1: 225-247.
146. Josting A, Nogová L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23: 1522-1529.
147. Tzankov A, Krugmann J, Fend F, et al. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: A clinicopathological study of 119 cases. Clin Cancer Res 2003; 9: 1381-1386.
148. Molot RJ, Mendenhall NP, Barré DM, Braylan RC. The clinical relevance of L26, a B-cell-specific antibody in Hodgkin's disease. Am J Clin Oncol 1994; 17: 185-188.
149. Donnelly GB, Filippa D, Moskowitz CH, et al. Increased treatment failure in patients with CD20 positive classic Hodgkin disease (HD). Blood 1999; 94: 598A.
150. Rassidakis GZ, Medeiros LJ, Viviani S, et al. CD20 expression in Hodgkin disease and Reed-Sternberg cells of classical Hodgkin's disease: Associations with presenting features and clinical outcome. J Clin Oncol 2002; 20: 1278-1287.
151. Portlock CS, Donnelly GB, Qin J, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol 2004; 125: 701-708.
152. Canioni D, Deau-Fischer B, Taupin P, et al. Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: A study of 59 cases. PLoS One 2009; 4: e6341.
153. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
154. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002; 359: 2065-2071.
155. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry. Société Francaise de Greffe de Moelle. Bone Marrow Transplant 1997; 20: 21-26.
156. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13: 1628-1635.
157. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemo-radiotherapy second-line program for relapsed and refractory Hodgkin's disease: Analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
158. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine (IGEV): A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007; 92: 35-41.
159. Balsalobre P, Díez-Martín JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009; 27: 2192-2198.
160. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 1993; 11: 2342-2350.
161. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 142: 72-78.
162. Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314-4321.
163. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.European Bone Marrow Transplantation (EBMT) Lymphoma Registry. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678.
164. Robinson SP, Goldstone AH, Mackinnon S, et al. Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.
165. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934-1941.
166. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: Low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2003; 35: 943-951.
167. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish Prospective Cooperative Protocol. Biol Blood Marrow Transplant 2006; 12: 172-183.